NCT07003256Completed
Observational Study: Romiplostim for Platelet Recovery in Haploidentical HSCT
An Observational Study on the Promotion of Platelet Recovery by Romiplostim During Haploidentical Hematopoietic Stem Cell Transplantation
Source: ClinicalTrials.gov · Last updated 28 Jul 2026
Brief summary (registry, in English)
The objective of this observational study is to explore the long-term effects of roprastine given to promote platelet implantation in hematopoietic stem cell hemicongruent transplantation in children with thalassemia. The main questions it aimed to answer is: Is roprastine safe and effective for platelet implantation in children with thalassemia hemicongruent transplantation? Participants who have already received roprastine as part of routine medical care for hematopoietic stem cell hemicongruent transplantation in children with thalassemia will answer online survey questions about the effects of their platelet implantation within 8 weeks.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 16 (actual)
- First submitted
- 15 May 2025
- Start date
- 1 Sept 2024
- Primary completion date
- 30 Apr 2026
- Lead sponsor
- Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
- Diseases
- Thalassaemia
- NCT number
- NCT07003256
What you commit to
- Study type: Observational
- Participants enrolled: 16
- From 1 Sept 2024 to the primary completion date, 30 Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- There is a fully matched donor, and transplantation with a half - matched donor is not agreed.
- Donor specific antibody Greater than 5000, and after antibody treatment, it should not be lower than 3000.
- After evaluation by the transplantation team, there are contraindications for transplantation.
Other illness
- Positive for hepatitis B DNA.
- There is an active infection.
Lab values
- For donors and recipients, the transaminase is more than twice the normal value.
Who the study is looking for
- After undergoing Mediterranean gene testing, reviewing the history of blood transfusions, and conducting a blood routine examination, the patient was diagnosed with severe thalassemia.
- Children aged 2 - 17 years old.
- Agree to the haploidentical transplantation, and the team has evaluated that there are no transplantation contraindications.
Age in the registry: 2 years to 17 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Haikou Affiliated Hospital of Central South University Xiangya School of Medicine Coordinator of this site? Confirm its status | Haikou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.